Improvements and gaps in reaching treatment goals for patients with hereditary angioedema
The contents of this post were first presented at a poster talk during the annual scientific meeting of the American College of Allergy, Asthma & Immunology’s November 2022 symposium.
Hereditary angioedema (HAE) is a genetic disorder that results in unpredictable episodes of severe swelling and can be life threatening. The swelling can affect different parts of the body and can be painful and debilitating. Attacks can even last for a few days. Fortunately, treatments are available that help prevent attacks when taken regularly. These treatments are called long-term prophylaxis (LTP). In this blog post I look at how much has improved for HAE patients and where there is still room for improvement towards reaching the established treatment goal of normalizing patients’ lives.
Steps in the right direction
Three long-term prophylactic therapies used to treat HAE due to C1-inhibitor deficiency have become available in the past five years. We wanted to see if use of healthcare resources (such as visits to emergency rooms or filling prescriptions of medication for relief of acute HAE symptoms) by patients with HAE had decreased in the real world after those treatments became available. Use of real-world data, in addition to data generated during clinical trials, is critical to building an understanding of a treatment’s efficacy.
We looked at data from an anonymized US insurance claims database in adults treated with selected LTP for a minimum of 180 days. We found ~40-50 new users of each of the treatments of interest, with similar characteristics between the two groups.
We found that the annualized use of healthcare decreased by greater than 50% after treatment initiation:
- Medication fills for relief of acute HAE symptoms dropped from ~10 to 3-4 per year
- Emergency visits/hospitalizations due to HAE dropped from 1-2 to ~0.5 per year
Our conclusion is that, while LTP treatments reduced resource use and costs considerably, they did not eliminate the need for continued prescriptions and hospitalization. Use of these LTP treatments also cost between ~$730,000 to $870,000, with pharmacy costs accounting for >95% of total costs.
More from BioMarin
As we reflect on the progress of the last quarter century, we take this opportunity to also look forward to what’s next for BioMarin. In our continued pursuit to maximize impact for patients, we continue to ask ourselves: what more can we do? The outcome of this ongoing self-assessment has helped bring clarity to how we can best deliver on our purpose – to transform lives through genetic discovery.
By interrogating the human genome, we’ve designed therapies that address the root cause of genetic disease. That’s a guiding principle for how we approach our research at BioMarin, and nowhere is that more true than in our work researching gene therapy. As part of our commitment to expanding our technical expertise, we’re looking into many […]
At Howard University, we’re focused on providing our students with valuable experiences that prepare them to become future biopharmaceutical industry leaders. When our College of Pharmacy looked to collaborate with an organization to develop a fellowship in Regulatory Affairs, we wanted a partner that not only thinks strategically about the issues facing the pharmaceutical industry […]